Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HAIC GP regimen combined with intraoperative arterial envafolimab plus lenvatinib for unresectable biliary tract cancer
ChiCTR2600132815Phase 4Not yet recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Jul 2026
- Modality
- Small Molecules, Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of envafolimab, lenvatinib, gemcitabine and cisplatin in biliary cancer (4 arms), sponsored by West China Hospital of Sichuan University. Primary endpoint: Objective response rate. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
envafolimablenvatinibgemcitabinecisplatin
03
Conditions
biliary cancer
Beyond the preview
Go deeper on ChiCTR2600132815.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600132815.